Market Neuron Logo
⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

CRISIL - Investment Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Back to Investment List

πŸ“Š Investment Rating: 3.7

CRISIL Ltd. is a fundamentally strong player in the financial analytics and ratings space, but its current valuation and technical indicators suggest caution for long-term investors. Here's a full breakdown

βœ… Strengths for Long-Term Investment

Exceptional Profitability

ROCE: 35.6% β€” highly efficient capital deployment

ROE: 27.8% β€” strong shareholder returns

Consistent Earnings

EPS: β‚Ή99.5 β€” robust earnings base

PAT Qtr: β‚Ή172 Cr vs β‚Ή160 Cr β€” 14.3% growth

Low Leverage

Debt-to-equity: 0.11 β€” minimal financial risk

Institutional Confidence

FII holding up 0.39% β€” foreign investors showing interest

⚠️ Valuation & Technical Concerns

Overvaluation Risks

P/E: 53.5 vs Industry PE of 31.8 β€” trading at a premium

PEG Ratio: 3.34 β€” suggests overvaluation relative to growth

Weak Momentum

RSI: 31.0 β€” nearing oversold territory

MACD: -40.8 β€” bearish crossover

Price below 50 DMA (β‚Ή5,587) and near 200 DMA (β‚Ή5,142) β€” trend reversal possible

Dividend Yield: 0.17% β€” not attractive for income investors

DII Holding Decline: -0.32% β€” slight dip in domestic investor sentiment

πŸ“ˆ Ideal Entry Price Zone

To reduce valuation risk, consider accumulating in the β‚Ή4,900–₹5,100 range

This zone is near the 200 DMA and offers better margin of safety

RSI and MACD suggest weakness β€” wait for stabilization or reversal signals

🧭 Exit Strategy / Holding Period

If you're already holding the stock

Holding Period: 3–5 years to benefit from sector resilience and global expansion

Exit Strategy

Partial Exit near β‚Ή6,800–₹6,950 (52-week high) if valuation remains stretched

Hold if ROE stays above 25% and PEG drops below 2.0

Monitor quarterly PAT and EPS β€” any stagnation may warrant trimming

Would you like a peer comparison with other financial analytics or rating agencies to benchmark CRISIL’s potential?

Edit in a page

Back to Investment List